Technology evaluation: pegaptanib, Eyetech/Pfizer.
Technology evaluation: pegaptanib, Eyetech/Pfizer.
复制标题
技术评估：pegaptanib、Eyetech/Pfizer。
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
S. Vinores
中科院分区：
文献类型：
--
作者：
S. Vinores
Eyetech制药公司和辉瑞公司正在共同开发抗血管内皮生长因子适配子pegaptanib，作为一种血管生成抑制剂，除了治疗其他眼病外，还可能治疗老年性黄斑变性和糖尿病黄斑水肿。吉利德之前曾研究适体对癌症的潜在治疗作用，然而，自1999年以来，就没有公布过这一适应症的数据。
Eyetech Pharmaceuticals and Pfizer are co-developing the anti-vascular endothelial growth factor aptamer, pegaptanib, as an angiogenesis inhibitor for the potential treatment of age-related macular degeneration and diabetic macular edema, in addition to other ocular diseases. Gilead was previously investigating the aptamer for the potential treatment of cancer, however, no data have been published for this indication since 1999.